Rolf Wahlquist
Papers
1
Total Citations
7
H-Index
1
About
Rolf Wahlquist is a leading urologic oncologist whose research focuses on testicular cancer, specifically refining surgical approaches to reduce long-term treatment toxicity. His major contribution lies in challenging the traditional paradigm for stage II seminoma, where chemotherapy and radiotherapy—though highly effective—carry significant risks of cardiovascular disease, secondary malignancies, and other late effects. Wahlquist’s landmark collaborative study, combining data from the SWENOTECA group and Cologne, demonstrated that primary retroperitoneal lymph node dissection (RPLND) is a safe and effective alternative for patients with stage IIA-IIC seminoma with nodes ≤3 cm. This work has reshaped clinical guidelines, offering young patients a chemotherapy-sparing option with excellent oncologic outcomes. While his most-cited paper currently has 7 citations, its impact is rapidly growing as the field moves toward de-escalation strategies. Wahlquist’s research is pivotal for students and clinicians interested in testicular cancer, surgical oncology, and survivorship-focused treatment de-intensification—showing that less aggressive intervention can maintain cure rates while dramatically improving quality of life.
Research Focus
Key Achievements
Top Papers
- 1